role of specialized pro resolving mediators in neuropathic pain

• DOI: 10.5281/zenodo.6204705
• Publication Date: 2021-08-11
• Authors: Alessandro Leuti; Alessandro Leuti; Marina Fava; Marina Fava; Niccolò Pellegrini; Mauro Maccarrone; Mauro Maccarrone
• Keywords: resolution of inflammation; neuropathic pain; Pharmacology; 0301 basic medicine; chronic inflammation; 0303 health sciences; chronic inflammation; neuroinflammation; neuropathic pain; resolution of inflammation; resolution of inflammatory pain; RM1-950; neuroinflammation; 3. Good health; : resolution of inflammation, chronic inflammation, neuropathic pain, neuroinflammation, resolution of inflammatory pain; 03 medical and health sciences; resolution of inflammatory pain; Therapeutics. Pharmacology

Inflammation and neuroinflammation are critical mechanisms in the generation of neuropathic pain that is experienced in several chronic diseases. The aberrant inflammation that triggers this pathophysiologic process can be tracked down to an exacerbated immune response, which establishes a vicious cycle and continuously recruits inflammatory cells by inducing chronic tissue damage. Recently, impairment of the cellular and molecular machinery orchestrated by specialized pro-resolving mediators (SPMs)—i.e., endogenous lipids termed resolvins, protectins, maresins, and lipoxins that confine the inflammatory cascades in space and time during the “resolution of inflammation”–has emerged as a crucial event in the derangement of the inflammatory homeostasis and the onset of chronic inflammation and pain. Indeed, a deviant inflammatory response that is not adequately controlled by the resolution network leads to the overproduction of pro-inflammatory eicosanoids that, opposite to SPMs, lead to neuropathic pain. Interestingly, in the last two decades convincing evidence has demonstrated that SPMs antagonize the in vivo activity of pro-inflammatory eicosanoids and, overall, exert potent anti-hyperalgesic effects in a number of pain-associated paradigms of disease, such as arthritis and chemotherapy-induced peripheral neuropathy, as well as in many experimental models of pain like mechanical allodynia, chemical pain, heat hypersensitivity and phase 1 and 2 inflammatory pain. Of note, accumulated evidence supports a synergy between SPMs and other signalling pathways, such as those mediated by transient receptor potential (TRP) channels and those triggered by opioid receptors, suggesting that the cascade of events where inflammation and pain perception take part might be ways more intricated than originally expected. Here, we aim at presenting a state-of-the-art view of SPMs, their metabolism and signalling, in the context of cellular and molecular pathways associated to neuropathic pain.